HalioDx: HalioDx

IMMUNOSCORE®

Scoring Immune Response in Colon Cancer

For unmatched clinical performance in routine settings

More info

IMMUNOSCORE® IC

in Non-Small Cell Lung cancer (NSCLC)

Combine PD-L1 with CD8 to improve predictive value of PD-L1

More info

BIOPHARMA SERVICES

An integrative approach

A 360° view of the cancer immune contexture of a given patient

More info

IVD DEVELOPMENT

For IVD assay development, CTA and CDX

Partnering with diagnostics and pharma companies

More info

Latest News

& Events

Date: On 2020-03-10
Location: Cambrige

Date: From 2020-03-12 to 2020-03-13
Location: London

In the media :

Tuesday 04 June 2019 - MyPharma Editions: HalioDx : Immunoscore® démontre son utilité clinique dans le cancer du colon de stade III | Wednesday 20 March 2019 - Spoke: Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio | Spoke | Thursday 14 March 2019 - MyPharma Editions: Transgene : le développement de myvac™ bénéficie d’une aide de 5,2 millions d’euros du Programme d’Investissements d’Avenir | Wednesday 13 March 2019 - Spoke: Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme | Spoke | Wednesday 14 November 2018 - Marseille Immunopole: RT @HalioDx: #Immunoscore Provides Risk Assessments for All Stages of #ColonCancer https://t.co/DjPKMRk2yY @TargetedOnc @JeromeGalon @sitcancer #SitC2018 https://t.co/Jag3zAcAS9 |